Penumbra Inc (NYSE:PEN) CEO Adam Elsesser sold 8,000 shares of the firm’s stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $141.58, for a total transaction of $1,132,640.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Adam Elsesser also recently made the following trade(s):
- On Monday, March 11th, Adam Elsesser sold 8,000 shares of Penumbra stock. The shares were sold at an average price of $139.86, for a total transaction of $1,118,880.00.
NYSE PEN traded down $2.78 on Monday, reaching $137.95. The company had a trading volume of 279,400 shares, compared to its average volume of 369,629. The company has a market cap of $4.89 billion, a P/E ratio of 270.49, a P/E/G ratio of 8.12 and a beta of 0.80. Penumbra Inc has a 12 month low of $110.84 and a 12 month high of $167.35.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC increased its holdings in Penumbra by 6.6% in the 4th quarter. FMR LLC now owns 5,024,916 shares of the company’s stock valued at $614,045,000 after acquiring an additional 310,996 shares during the last quarter. Vanguard Group Inc. increased its holdings in Penumbra by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,646,066 shares of the company’s stock valued at $396,116,000 after acquiring an additional 68,479 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Penumbra by 2.7% in the 3rd quarter. Vanguard Group Inc now owns 2,646,066 shares of the company’s stock worth $396,116,000 after buying an additional 68,479 shares in the last quarter. BlackRock Inc. grew its stake in shares of Penumbra by 1.1% in the 4th quarter. BlackRock Inc. now owns 1,579,005 shares of the company’s stock worth $192,957,000 after buying an additional 17,324 shares in the last quarter. Finally, Baillie Gifford & Co. grew its stake in shares of Penumbra by 35.8% in the 4th quarter. Baillie Gifford & Co. now owns 906,022 shares of the company’s stock worth $110,715,000 after buying an additional 239,008 shares in the last quarter. Institutional investors own 81.60% of the company’s stock.
Several analysts have recently commented on PEN shares. Canaccord Genuity raised their price objective on shares of Penumbra from $138.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, January 30th. ValuEngine upgraded shares of Penumbra from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Finally, Zacks Investment Research downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $143.17.
COPYRIGHT VIOLATION WARNING: This piece was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/15/adam-elsesser-sells-8000-shares-of-penumbra-inc-pen-stock-2.html.
Penumbra Company Profile
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Featured Article: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.